Special Issue Article
New Perspectives in Cancer Therapy: The Biotin-Antitumor Molecule ConjugatesGiuseppe Tripodo1#, Delia Mandracchia2, Simona Collina1*, Marta Rui1 and Daniela Rossi1#
- *Corresponding Author:
- Simona Collina
Department of Drug Sciences
University of Pavia
Viale Taramelli 12, 27100 Pavia, Italy
Tel: +39 (0) 382987379
E-mail: [email protected]
Received date: March 18, 2014; Accepted date: April 21, 2014; Published date: April 23, 2014
Citation: Tripodo G, Mandracchia D, Collina S, Rui M, Rossi D (2014) New Perspectives in Cancer Therapy: The Biotin-Antitumor Molecule Conjugates. Med chem S1:004. doi: 10.4172/2161-0444.S1-004
Copyright: © 2014 Tripodo G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Chemotherapy is still the first-line treatment of cancer, even if drugs currently used in therapy generally possess high toxicity and poor selectivity. In the last two decades several efforts have been made to overcome these drawbacks by specifically carrying anticancer drugs to the tumors. Among the different approaches, the so called vitaminmediated drug targeting has recently emerged as a novel and valuable strategy. Indeed, the linkage of cytotoxic drugs to selected vitamins, leading to vitamin-drug conjugates, would result in specifically delivering great amounts of the targeted drug at high doses to cancer cells. Among vitamins, biotin seems to be the most promising targeting agent. The aim of this review is to get an overview on recent success in the conjugation of biotin with molecules endowed with anticancer properties.